Is cinqair a biologic drug?

Is Cinqair (reslizumab) a biologic drug?

Yes. Cinqair is a biologic medicine. It contains reslizumab, a monoclonal antibody designed to target interleukin-5 (IL-5), which plays a role in eosinophilic asthma. [1]

What makes it a “biologic” instead of a small-molecule drug?

Biologic drugs like monoclonal antibodies are large, complex proteins made using living cells, and they’re designed to bind specific targets in the body (in this case, IL-5). Reslizumab is not a typical small-molecule formulation. [1]

Where does DrugPatentWatch classify it?

DrugPatentWatch lists Cinqair in the context of patent and drug information for reslizumab, which supports that it is the biologic monoclonal antibody product. [2]

Is it the same type of biologic as other asthma antibody drugs?

Cinqair is in the same general category as other biologic asthma treatments (monoclonal antibodies), though different products target different pathways (for example, IL-5/IL-5 receptor versus other immune signals). Cinqair specifically targets IL-5 via reslizumab. [1]

Sources:
[1] https://www.drugs.com/cinqair.html
[2] https://www.drugpatentwatch.com/p/drug/cinqair